Literature DB >> 2551833

Opioid receptor selectivity of peptide models of beta-endorphin.

J W Taylor1, E T Kaiser.   

Abstract

Two peptides, designed to contain structural models of the proposed hydrophilic linker domain (residues 6-12) and amphiphilic alpha-helical domain (residues 13-29) in beta-endorphin, have been tested for their abilities to mimic the opioid receptor selectivity profile of the natural hormone. In competitive binding assays employing guinea-pig brain membranes, both peptides displayed a much higher affinity for mu- and delta-opioid receptors than for kappa opioid receptors. Relative to beta-endorphin, the peptide models were 2-3 times more potent in the mu and kappa receptor binding assays, and about equipotent in the delta receptor binding assay. In guinea-pig ileum assays, one peptide was equipotent to beta-endorphin and the other was twice as potent. Like beta-endorphin, their actions on this tissue were highly sensitive to naloxone antagonism, indicating that they were mediated by mu receptors and not kappa receptors. In view of the design of the two peptide models, and their minimal homology to the natural hormone, these results provide additional evidence in support to our proposal for the functional conformation of beta-endorphin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2551833

Source DB:  PubMed          Journal:  Int J Pept Protein Res        ISSN: 0367-8377


  2 in total

Review 1.  Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations.

Authors:  V J Hruby; F al-Obeidi; W Kazmierski
Journal:  Biochem J       Date:  1990-06-01       Impact factor: 3.857

2.  Can amphipathic helices influence the CNS antinociceptive activity of glycopeptides related to β-endorphin?

Authors:  Yingxue Li; Lindsay St Louis; Brian I Knapp; Dhanasekaran Muthu; Bobbi Anglin; Denise Giuvelis; Jean M Bidlack; Edward J Bilsky; Robin Polt
Journal:  J Med Chem       Date:  2014-03-07       Impact factor: 7.446

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.